Fetting J H, Wilcox P M, Sheidler V R, Enterline J P, Donehower R C, Grochow L B
Cancer Treat Rep. 1985 Nov;69(11):1249-51.
We employed a structured interview to retrospectively study tastes and vomiting associated with the parenteral components of cyclophosphamide, methotrexate, and 5-FU in 45 patients with stage II-IV breast cancer. Sixteen patients (36%) reported tastes which generally occurred in each cycle within 30 minutes of parenteral drug administration, lasted less than or equal to 1 hour, and were bitter. Five patients recalled that tastes seemed to produce vomiting. Tasting was significantly associated with postchemotherapy (P less than 0.01) but not anticipatory vomiting. Employing logistic regression techniques, tasting did not significantly improve prediction of anticipatory vomiting by postchemotherapy vomiting. Tastes may be produced by the action of plasma or salivary cyclophosphamide, methotrexate, and 5-FU on taste buds. While tastes might cause some vomiting, they are not necessary for it. Because this was a retrospective study with a small sample, these findings require confirmation.
我们采用结构化访谈对45例II-IV期乳腺癌患者进行回顾性研究，以了解与环磷酰胺、甲氨蝶呤和5-氟尿嘧啶非肠道用药相关的味觉和呕吐情况。16例患者（36%）报告有味觉异常，通常在每个周期非肠道给药后30分钟内出现，持续时间小于或等于1小时，且味觉发苦。5例患者回忆说味觉异常似乎会引发呕吐。味觉异常与化疗后呕吐显著相关（P<0.01），但与预期性呕吐无关。采用逻辑回归技术分析，味觉异常并不能显著改善通过化疗后呕吐对预期性呕吐的预测。味觉异常可能是血浆或唾液中的环磷酰胺、甲氨蝶呤和5-氟尿嘧啶作用于味蕾所致。虽然味觉异常可能会导致一些呕吐，但并非呕吐的必要条件。由于这是一项小样本的回顾性研究，这些发现需要进一步证实。
